WHP completes ADC Bio’s £5m cleanroom in UK site

By Vassia Barba contact

- Last updated on GMT

ADC Bio's bioconjugation manufacturing site in Deeside, North Wales, UK
ADC Bio's bioconjugation manufacturing site in Deeside, North Wales, UK

Related tags: ADC Bio, facility, Cleanroom facilities, Antibody drug conjugates

WHP completes the building of a cleanroom facility at a site expected to deliver ‘the next generation of anticancer blockbuster ADC drugs’.

WHP announced the completion of a cleanroom facility in Deeside, North Wales, UK, for ADC Bio, a biotechnology company developing anti-cancer, antibody drug conjugates (ADCs), under a £5m ($6.21m) contract. 

The engineering company was awarded the contract to design, build, test and validate the current good manufacturing practice (cGMP) cleanroom within ADC Bio’s existing 6,500-square-meter facility, in December 2017.

ADC Bio's conjugation suite
ADC Bio's conjugation suite

The cleanroom adds to the company’s bioconjugation manufacturing plant, with support areas for washing, depyrogenation, thawing and buffer preparation, and it is expected to boost the company’s commercial production of anti-cancer drugs.

According to WHP, ADCs are “a class of emerging biotherapeutics that require a bespoke infrastructure to ensure strict compliance with the highest global regulatory standards.”​ The company suggested the facility will deliver “the next generation of anticancer blockbuster ADC drugs”.

The cleanroom includes complex zoned heating, ventilation, and air conditioning to maintain segregation, cleanliness, air pressures, and other environmental controls. It was developed in compliance with UK Medicines and Healthcare products Regulatory Agency’s regulations.

A key feature of the project, according to ADC, has been the installation of a bespoke low maintenance toxic waste system, which removes cleanroom waste to a holding tank, and transports it to an off-site incinerator, preventing the possibility of onsite contamination.

Chris Douglas, WHP’s project manager, said: “The new cleanroom meets ADC Bio’s need to expand operations at Deeside beyond R&D to include safe, secure and highly efficient manufacturing capabilities.”

Related news

Show more

Related products

show more

Seasonal Vaccine Manufacturing

Seasonal Vaccine Manufacturing

Baxter BioPharma Solutions | 10-Feb-2021 | Technical / White Paper

The production of seasonal vaccines, such as those for influenza, presents unique challenges to manufacturers due to the necessary time constraints resulting...

Consideration and Options for Prefilled Syringes

Consideration and Options for Prefilled Syringes

Baxter BioPharma Solutions | 10-Feb-2021 | Technical / White Paper

Convenience, product differentiation, and less waste are great reasons for developing a product in a prefilled syringe. Baxter’s whitepaper describes the...

Rapid Biosafety Testing Enables the Future of Manufacturing

Rapid Biosafety Testing Enables the Future of Manufacturing

Viral Safety for mAb: Prevent, Detect, Remove | 23-Nov-2020 | Technical / White Paper

This white paper explores the factors driving the evolution toward faster biosafety testing and describes rapid approaches for adventitious agent testing...

Related suppliers

Follow us

Products

View more

Webinars